REFERENCES
1. Carmichael K, Sullivan B, Lopez E, Sun L, Cai H. Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinson’s disease. Ageing Neurodegener Dis 2021;1:4.
2. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 2018;8:S3-8.
3. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223-36; discussion 222.
4. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016;139 Suppl 1:318-24.
6. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 2016;76:759-77.
7. Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 2015;132:96-168.
8. Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci 2018;12:612.
9. Dudman JT, Krakauer JW. The basal ganglia: from motor commands to the control of vigor. Curr Opin Neurobiol 2016;37:158-66.
10. Wu J, Kung J, Dong J, et al. Distinct connectivity and functionality of aldehyde dehydrogenase 1a1-positive nigrostriatal dopaminergic neurons in motor learning. Cell Rep 2019;28:1167-81.e7.
11. Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 2012;74:858-73.
12. McGregor MM, McKinsey GL, Girasole AE, Bair-Marshall CJ, Rubenstein JLR, Nelson AB. Functionally distinct connectivity of developmentally targeted striosome neurons. Cell Rep 2019;29:1419-28.e5.
13. Evans RC, Twedell EL, Zhu M, Ascencio J, Zhang R, Khaliq ZM. Functional Dissection of basal ganglia inhibitory inputs onto substantia nigra dopaminergic neurons. Cell Rep 2020;32:108156.
14. Carmichael K, Evans RC, Lopez E, et al. Function and regulation of ALDH1A1-positive nigrostriatal dopaminergic neurons in motor control and Parkinson’s disease. Front Neural Circuits 2021;15:644776.
15. Davis MI, Crittenden JR, Feng AY, et al. The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra. PLoS One 2018;13:e0191436.
16. Crittenden JR, Tillberg PW, Riad MH, et al. Striosome-dendron bouquets highlight a unique striatonigral circuit targeting dopamine-containing neurons. Proc Natl Acad Sci U S A 2016;113:11318-23.
17. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
19. Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016;41:80-102.
20. Lovinger DM, Mathur BN. Endocannabinoids in striatal plasticity. Parkinsonism Relat Disord 2012;18 Suppl 1:S132-4.
21. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009;89:309-80.
22. Mátyás F, Urbán GM, Watanabe M, et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 2008;54:95-107.
23. Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003;163:463-8.
24. Gao Y, Vasilyev DV, Goncalves MB, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 2010;30:2017-24.
25. Tanimura A, Yamazaki M, Hashimotodani Y, et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 2010;65:320-7.
26. Reisenberg M, Singh PK, Williams G, Doherty P. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2012;367:3264-75.
27. Liu Z, Yang N, Dong J, et al. Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. Nat Commun 2022;13:3490.
28. Pisani V, Madeo G, Tassone A, et al. Homeostatic changes of the endocannabinoid system in Parkinson’s disease. Mov Disord 2011;26:216-22.
29. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020;16:9-29.
30. Marchioni C, Santos-Lobato BL, Queiroz MEC, Crippa JAS, Tumas V. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias. J Neural Transm 2020;127:1359-67.
31. Kelly R, Bemelmans AP, Joséphine C, Brouillet E, McKernan DP, Dowd E. Time-course of alterations in the endocannabinoid system after viral-mediated overexpression of α-synuclein in the rat brain. Molecules 2022;27:507.
32. Tesson C, Bouchetara MS, Ferrien M, Lesage S, Brice A. Identification of a DAGLB mutation in a non-Chinese patient with Parkinson’s disease. Mov Disord 2023;38:1756-7.
33. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 2012;76:70-81.
34. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008;14:923-30.
35. Oudin MJ, Hobbs C, Doherty P. DAGL-dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis. Eur J Neurosci 2011;34:1634-46.
36. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14:1347-56.
37. Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010;15:474-83.
38. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
39. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. In: Pertwee RG, editor. Cannabinoids. Berlin/Heidelberg: Springer-Verlag; 2005. pp. 299-325.
40. Nyíri G, Cserép C, Szabadits E, Mackie K, Freund TF. CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 2005;136:811-22.
41. Ramirez SH, Haskó J, Skuba A, et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 2012;32:4004-16.
42. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010;58:1017-30.
43. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry 2016;79:516-25.
44. Albarran E, Sun Y, Liu Y, et al. Postsynaptic synucleins mediate endocannabinoid signaling. Nat Neurosci 2023;26:997-1007.
45. Covey DP, Mateo Y, Sulzer D, Cheer JF, Lovinger DM. Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology 2017;124:52-61.
46. Varvel SA, Lichtman AH. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 2002;301:915-24.
47. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530-4.
48. Kishimoto Y, Kano M. Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. J Neurosci 2006;26:8829-37.
49. Hilário MR, Clouse E, Yin HH, Costa RM. Endocannabinoid signaling is critical for habit formation. Front Integr Neurosci 2007;1:6.
50. Sagheddu C, Muntoni AL, Pistis M, Melis M. Chapter Seven - Endocannabinoid signaling in motivation, reward, and addiction: influences on mesocorticolimbic dopamine function. Int Rev Neurobiol 2015;125:257-302.
52. Crittenden JR, Yoshida T, Venu S, Mahar A, Graybiel AM. Cannabinoid receptor 1 is required for neurodevelopment of striosome-dendron bouquets. eNeuro 2022;9:ENEURO.0318-21.2022.
53. Yanovsky Y, Mades S, Misgeld U. Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra. Neuroscience 2003;122:317-28.
54. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997;8:649-52.
55. Cheer JF, Kendall DA, Mason R, Marsden CA. Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology 2003;44:633-41.
56. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-50.
57. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004;24:4393-400.
58. Cheer JF, Wassum KM, Sombers LA, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 2007;27:791-5.
59. Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol 2007;72:612-21.
60. Bainbridge MN, Mazumder A, Ogasawara D, et al. Rady Children’s Institute for Genomic Medicine; Undiagnosed Disease Network. Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain 2022;145:3383-90.
61. Dong A, He K, Dudok B, et al. A fluorescent sensor for spatiotemporally resolved endocannabinoid dynamics in vitro and in vivo. bioRxiv. [Preprint] Oct 20, 2020 [accessed on 2024 Aug 1]. Available from: https://doi.org/10.1101/2020.10.08.329169.
62. Farrell JS, Colangeli R, Dong A, et al. In vivo endocannabinoid dynamics at the timescale of physiological and pathological neural activity. Neuron 2021;109:2398-403.e4.
63. Malheiro RF, Carmo H, Carvalho F, Silva JP. Cannabinoid-mediated targeting of mitochondria on the modulation of mitochondrial function and dynamics. Pharmacol Res 2023;187:106603.
64. Hempel B, Crissman M, Pari S, et al. PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice. Mol Psychiatry 2023;28:4203-14.
65. Davies AK, Alecu JE, Ziegler M, et al. AP-4-mediated axonal transport controls endocannabinoid production in neurons. Nat Commun 2022;13:1058.
66. Agarwal D, Sandor C, Volpato V, et al. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nat Commun 2020;11:4183.
67. Nichterwitz S, Chen G, Aguila Benitez J, et al. Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling. Nat Commun 2016;7:12139.
68. Shonesy BC, Parrish WP, Haddad HK, et al. Role of striatal direct pathway 2-arachidonoylglycerol signaling in sociability and repetitive behavior. Biol Psychiatry 2018;84:304-15.
69. Augustin SM, Gracias AL, Luo G, Anumola RC, Lovinger DM. Striatonigral direct pathway 2-arachidonoylglycerol contributes to ethanol effects on synaptic transmission and behavior. Neuropsychopharmacology 2023;48:1941-51.
70. Luján MÁ, Covey DP, Young-Morrison R, et al. Mobilization of endocannabinoids by midbrain dopamine neurons is required for the encoding of reward prediction. Nat Commun 2023;14:7545.
71. Escamilla-Ramírez A, García E, Palencia-Hernández G, et al. URB597 and the cannabinoid WIN55,212-2 reduce behavioral and neurochemical deficits induced by MPTP in mice: possible role of redox modulation and NMDA receptors. Neurotox Res 2017;31:532-44.
72. Batista LA, Cabral LM, Moreira TS, Takakura AC. Inhibition of anandamide hydrolysis does not rescue respiratory abnormalities observed in an animal model of Parkinson’s disease. Exp Physiol 2022;107:161-74.
73. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002;99:10819-24.
74. Makara JK, Mor M, Fegley D, et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 2005;8:1139-41.
75. Fernández-Suárez D, Celorrio M, Riezu-Boj JI, et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol Aging 2014;35:2603-16.
76. Mounsey RB, Mustafa S, Robinson L, et al. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Exp Neurol 2015;273:36-44.
77. Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011;334:809-13.
78. Zanfirescu A, Ungurianu A, Mihai DP, Radulescu D, Nitulescu GM. Targeting monoacylglycerol lipase in pursuit of therapies for neurological and neurodegenerative diseases. Molecules 2021;26:5668.
79. Fernandez-Espejo E, Caraballo I, de Fonseca FR, et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 2005;18:591-601.
80. Bassi M, Sancesario A, Morace R, Centonze D, Iezzi E. Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res 2017;2:21-9.
81. Wang M, Liu H, Ma Z. Roles of the cannabinoid system in the basal ganglia in Parkinson’s disease. Front Cell Neurosci 2022;16:832854.
82. Chagas MHN, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 2014;28:1088-98.
83. Kelly R, Joers V, Tansey MG, McKernan DP, Dowd E. Microglial phenotypes and their relationship to the cannabinoid system: therapeutic implications for Parkinson’s disease. Molecules 2020;25:453.
84. Jehle J, Hoyer FF, Schöne B, et al. Myeloid-specific deletion of diacylglycerol lipase α inhibits atherogenesis in ApoE-deficient mice. PLoS One 2016;11:e0146267.
85. Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF. DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol 2012;8:999-1007.
86. Finseth TA, Hedeman JL, Brown RP 2nd, Johnson KI, Binder MS, Kluger BM. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in colorado. Evid Based Complement Alternat Med 2015;2015:874849.
87. Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 2014;37:41-4.
88. Chagas MHN, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 2014;39:564-6.
89. Yan S, Lu J, Duan B, et al. Quantitative susceptibility mapping of multiple system atrophy and Parkinson’s disease correlates with neurotransmitter reference maps. Neurobiol Dis 2024;198:106549.
90. Pasquarelli N, Porazik C, Bayer H, et al. Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson’s disease. Neurochem Int 2017;110:14-24.
